OptiBiotix Health PLC Presentation of data at European Conference (0536C)
January 17 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0536C
OptiBiotix Health PLC
17 January 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Presentation of research data at European Conference: ProBiota
2018
OptiBiotix Health plc (AIM:OPTI), a life sciences business
developing compounds to tackle obesity,high cholesterol,
diabetes and skin care, announces that it has had an abstract
accepted for presentation at ProBiota 2018 in Barcelona from 7-9
February 2018. ProBiota is the leading annual event for the global
prebiotic, probiotic and the microbiome focused food and pharma
industries. The conference is world renowned as a key meeting place
for a community of scientists and industry leaders who want to
translate science into new products in the growing supplements and
ingredients market.
The abstract reports on the identification and development of a
prebiotic which selectively enhances the growth of Lactobacillus
rhamnosus GG ("LGG(R) ") in the gut. LGG(R) is the world's best
documented probiotic strain and has been described in more than
1000 scientific publications and 300 clinical studies. Christian
Hansen acquired the rights and related business for LGG(R) for a
cash consideration of EUR73 million in September 2016. LGG(R) is
contained within DSM's Culturelle(R) probiotic range which is the
best-selling probiotic supplement brand in the world.
The abstract will be presented as a poster and oral presentation
and demonstrates OptiBiotix's ability to identify and develop
targeted prebiotics which can selectively enhance the growth rate
and health benefits of specific microbial species, and in doing so
enhance the efficacy of probiotic products. This new product
concept utilises OptiBiotix's patented approach to the development
of optimised synbiotics with the potential to enhance probiotic
health benefits, and provide product differentiation in a probiotic
market forecast to be worth more than $46.5bn by 2020 (Markets and
Markets).
OptiBiotix has filed patents protecting its discoveries of an
optimised prebiotic for Lactobacillus rhamnosus, and LGG(R), adding
to to its extensive existing IP portfolio in this area.
Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We believe
this is the first reported publication of an optimised synbiotic
for LGG(R) , one of the world's best documented and best-selling
probiotic brands. The development of species specific prebiotics
which can selectively enhance the growth and health benefits of
existing probiotic products is a growing area of interest to the
probiotic industry. The ability to create designer prebiotics which
can selectively modulate the growth of an individual species and be
used in combination to improve the efficacy of existing probiotics,
or by itself to modify an individual's microbiome to improve
health, is a hugely exciting development in global microbiome
research and product development. We believe we are fast
approaching a future where microbiome products will make a
significant contribution to the prevention, management and
treatment of disease. The ability to create designer ingredients
which can precision engineer the microbiome to improve health
places OptiBiotix at the forefront of this global health
trend."
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
FinnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020
7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBFMFTMBJBBIP
(END) Dow Jones Newswires
January 17, 2018 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024